BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma.

摘要: Abstract The serine/threonine-protein kinase B-raf (BRAF) is an oncogene mutated in various neoplasms, including 5-15% of colorectal carcinomas. T1799A point mutation, responsible for a large majority these alterations, results amino acid substitution (V600E) causing the constitutive activation protein cascade. BRAF V600E MLH1 deficient tumors implicates somatic tumor-only methylation promoter region instead germline mutation. also predicts poor prognosis microsatellite stable cancers and may be marker resistance to anti-EGFR therapy metastatic disease. Currently, only molecular methods are available assessing mutational status. An immunohistochemical approach evaluated here. Colon from 2008 2012 tested by pyrosequencing mutation were selected. A total 31 with (n = 14) without 17) analyzed immunohistochemistry using commercially antibody specific V600E-mutated protein. All 14 carcinomas demonstrated cytoplasmic positivity tumor cells anti-BRAF antibody. In minority cases, staining intensity samples was weak 2) or heterogeneous 4); however, cases showed diffuse, strong (8 cases). None 17 wild-type immunoreactivity overall sensitivity specificity assay 100%. Detection cancer viable alternative methods. © 2013 Wiley Periodicals, Inc.